OrbiMed's 12% stake set to support Shasun's expansion
This article was originally published in Scrip
Executive Summary
OrbiMed, a leading US investment firm dedicated to the healthcare sector, is acquiring about 12% of Shasun Pharmaceuticals of India for Rs500 million ($10.2 million).